Ekso Bionics Holdings (NASDAQ: EKSO) has announced that it has entered into an agreement with Israel-based closely-held MediTouch (MediTouch) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor rehabilitation system in the U.S.
The BalanceTutor is the only known rehabilitation system that employs an advanced 4D perturbation patented treadmill and multiple force and movement sensors, which allow patients impacted by impaired balance to react to unanticipated disturbances while walking. The BalanceTutor 4D treadmill can move forward, backward, and side-to-side while a patient is standing still or walking to elicit a slip, trip, or stumble. Patient weight is supported by an overhead frame that is designed to promote safe responses to disturbances of balance without the patient risk of experiencing a fall. The BalanceTutor’s proprietary 4D perturbations mimic realistic balance challenges that require a reactive response while maintaining patient and physical therapist safety.
In a statement, Scott Davis, CEO of Ekso Bionics, commented, “We are excited to add MediTouch’s BalanceTutor rehabilitation system to our leading technology offerings, expanding our reach in patient care. We believe the BalanceTutor is synergistic with our current go-to-market strategy by leveraging a common customer call point with a technology that is complementary to our current enterprise health exoskeleton solutions. We look forward to working with MediTouch to help ensure that the groundbreaking BalanceTutor gains awareness, acceptance and adoption by inpatient and outpatient physical rehabilitation facilities across the country.”
Moshe Druker, VP of Global Business Development at MediTouch, remarked, “We are thrilled to partner with Ekso Bionics to grow the presence of the BalanceTutor across the U.S. This collaboration marks an important milestone for MediTouch, enabling us to expand access to our innovative rehabilitation technology and help more individuals regain balance, confidence, and independence.”
